KLF2 and atherosclerosis: Similarly, aloperine treatment also reduced oxidized low-density lipoprotein, a marker of endothelial inflammation, and reduced MCP-1, VCAM-1, IL-6, and E-selection by reducing Kruppel-like factor 2 (KLF2) expression, suggesting the potential anti-atherosclerosis characteristics [105].